3,4-Dihydroxy-6-[18F]-Fluoro-L-Phenylalanine Positron Emission Tomography in Patients With Central Motor Disorders and in Evaluation of Brain and Other Tumors
Section snippets
Pathophysiology and Treatment of Movement Disorders
In the nearly 200 years since the first modern clinical description of the spectrum of bradykinesia, tremor, and gait disturbance by James Parkinson, there has been tremendous progress in the understanding and clinical management of movement disorders.4 Neuroimaging methods, especially positron emission tomography (PET) and single-photon emission computed tomography (SPECT), have now assumed an important role in the refinement in understanding of differential diagnosis and clinical course by
18F-FDOPA in the Evaluation of Brain Tumors
Malignant brain tumors are a heterogeneous group of diseases, each with its own biology, prognosis, and treatment. The most common tumor types are metastatic tumors and malignant gliomas. In 2005, American Cancer Society estimated that primary brain tumor was the cause of death in approximately 12,760 people. Metastatic tumors are more common in that more than 100,000 people die per year with symptomatic intracranial metastases.57 The initial presentation and diagnostic approaches are similar
Other Tumors
In addition to the roles 18F-FDOPA PET has played in the evaluation of patients with central motor disorders and brain tumors, a growing literature has focused on the potential utility of imaging with 18F-FDOPA in the assessment of a number of conditions in which neuroendocrine tumors are suspected or known to be involved.
The neuroendocrine condition for which the role of 18F-FDOPA PET has been most extensively documented is carcinoid. For example, in a recent prospective study of the
Conclusions
The rapid elaboration of imaging biomarkers for PET and SPECT has resulted in significant changes in the potential approach to diagnosis and symptom management in the movement disorders, especially PD. The proliferation of readily available radiopharmaceuticals for assessing dopamine deficits raises the possibility of earlier and more accurate diagnosis with an algorithm which includes a rule-in diagnostic imaging examination, though there remain significant unanswered questions with regard to
Acknowledgment
We are indebted to Victoria Lau for her skillful assistance with manuscript preparation.
References (96)
- et al.
Positron emission tomography in clinical neurology
Mol Imaging Biol
(2004) - et al.
Treatment for the progression of Parkinson’s disease
Lancet Neurol
(2005) Disease modification in Parkinson’s disease
Lancet Neurol
(2004)- et al.
Challenges in Parkinson’s disease: Restoration of the nigrostriatal dopamine system is not enough
Lancet Neurol
(2004) - et al.
Genealogy, expression, and molecular mechanisms in apoptosis
Pharmacol Ther
(2004) Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease
Lancet Neurol
(2004)- et al.
[125I]RTI-55: A potent ligand for dopamine transporters
Eur J Pharmacol
(1991) Functional imaging in relation to parkinsonian syndromes
J Neurol Sci
(1993)- et al.
Parkinson’s disease: in vivo assessment of disease progression using positron emission tomography
Brain Res Mol Brain Res
(2005) - et al.
Staging of brain pathology related to sporadic Parkinson’s disease
Neurobiol Aging
(2003)